A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors

HS-10502 is a Poly(ADP-ribose) polymerase 1 (PARP1)-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 in subjects with homologous recombination repair (HRR) gene mutant or homologous recombination deficiency (HRD) positive advanced solid tumors.

HS-10502是一款聚(ADP-核糖)聚合酶1(Poly(ADP-ribose) polymerase 1，PARP1)特异性选择性抑制剂。本研究旨在评估HS-10502在携带同源重组修复(homologous recombination repair，HRR)基因变异或同源重组缺陷(homologous recombination deficiency，HRD)阳性的晚期实体瘤受试者中的安全性、耐受性、药代动力学(pharmacokinetics，PK)及疗效。